Haplotypes in the CYP2R1 gene are associated with levels of 25(OH)D and bone mineral density, but not with other markers of bone metabolism (MrOS Sweden)

PLoS One. 2018 Dec 21;13(12):e0209268. doi: 10.1371/journal.pone.0209268. eCollection 2018.

Abstract

Objective: Polymorphisms in the CYP2R1 gene encoding Vitamin D 25-hydroxylase have been reported to correlate with circulating levels of 25-OH vitamin D3 (25(OH)D). It is unknown whether these variations also affect overall bone metabolism. In order to elucidate the overall associations of polymorphisms in the CYP2R1, we studied haplotype tagging single nucleotide polymorphisms (SNPs) in the gene and serum levels of 25(OH)D, calcium, phosphate, parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF23), as well as bone mineral density (BMD).

Methods: Baseline data on serum parameters and BMD from MrOS Sweden, a prospective population-based cohort study of elderly men (mean age 75 years, range 69-81), were analyzed. Genotyping was performed for eight SNPs covering the CYP2R1 gene in 2868 men with available samples of DNA. Subjects were followed up concerning incidence of fracture during five years.

Results: There was a significant genetic association with circulating levels of 25(OH)D (4.6-18.5% difference in mean values between SNP alleles), but there were no correlations with levels of calcium, phosphate, PTH or FGF23 for any genetic variant. No differences were found in fracture incidence between the variants. There was an inverse relationship between lower BMD and concomitant higher 25(OH)D for three of the haplotypes (p < 0.005).

Conclusions: Common variants in the CYP2R1 gene encoding Vitamin D 25-hydroxylase correlate with levels of circulating 25(OH)D but do not otherwise associate with measures of calcium and phosphate homeostasis. Presence of the specific haplotypes may be an indicator of risk for low 25(OH)D levels, and may in addition be correlated to bone mineral density.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Bone Density / genetics*
  • Calcifediol / blood*
  • Calcium / blood
  • Cholestanetriol 26-Monooxygenase / genetics*
  • Cohort Studies
  • Cytochrome P450 Family 2 / genetics*
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / blood
  • Fractures, Bone / blood
  • Fractures, Bone / genetics
  • Haplotypes
  • Humans
  • Male
  • Parathyroid Hormone / blood
  • Phosphates / blood
  • Polymorphism, Single Nucleotide
  • Prospective Studies
  • Sweden

Substances

  • Biomarkers
  • FGF23 protein, human
  • PTH protein, human
  • Parathyroid Hormone
  • Phosphates
  • Fibroblast Growth Factors
  • Fibroblast Growth Factor-23
  • Cytochrome P450 Family 2
  • CYP2R1 protein, human
  • Cholestanetriol 26-Monooxygenase
  • Calcifediol
  • Calcium

Grants and funding

This work was supported by ALF (grant nr 2014/2018, Österlund (grant nr 2016), Herman Järnhardt (grant nr 2016), and The Swedish Research Council (2011-2535). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.